Wolverine Trading
GHDX

Wolverine Trading’s Genomic Health, Inc. GHDX Stock Holding History

Wolverine Trading’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,928
Closed -$351K – 5495
2019
Q1 		$415K Buy
5,928
+1,465
+33% +$109K ﹤0.01% 2986
2018
Q4 		$284K Buy
+4,463
New +$313K ﹤0.01% 3261

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Wolverine Trading's GHDX Position: Q2 2019 in Review

Wolverine Trading sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 5,928 shares — an estimated $351K sold.

Wolverine Trading first reported a position in GHDX in Q4 2018 and held it in 2 quarters. The position peaked at $415K in Q1 2019. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

  • Wolverine Trading reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
  • Wolverine Trading sold 5,928 Genomic Health, Inc. shares in Q2 2019, an estimated $351K.
  • Wolverine Trading first reported a position in Genomic Health, Inc. in Q4 2018 and held it in 2 quarters.
  • Wolverine Trading's Genomic Health, Inc. position peaked at $415K in Q1 2019.
  • 215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on Wolverine Trading's 13F filing for Q2 2019, filed 20 Aug 2019.